Will Gilead Sciences, Inc (NASDAQ:GILD) Stock Finally Breakout In 2017?

- December 16, 2016

GILD_stockAnyone with two eyes and basic understanding of fundamental analysis should be able to see that Gilead Sciences, Inc (NASDAQ:GILD) is undervalued. Furthermore, any reasonable investor should conclude that GILD stock won’t stay in the mid-70s forever; Gilead stock will go higher.

The question is not if, but when will GILD stock will go higher? Will it be in 2017, or later?

This is a company that has lost 31% of its market capitalization over the last year. GILD stock has fallen 25% in the same span, outperforming its market capitalization losses thanks to large buybacks.

While Gilead Sciences’ HCV franchise has peaked, this is still a company that’s valued at only 7x next year’s expected EPS. Never-mind that revenue is falling at a single-digit clip — focus on Gilead stock’s valuation, its buybacks, and a dividend yield of 2.5%. Furthermore, consider the bad investment sentiment, and the many catalysts that could instantly catapult a cheap GILD stock.

Specifically, Gilead Sciences has $32 billion in cash. It is one of the few companies that can afford to raise its dividend, double the pace of buybacks, and still complete a game-changing acquisition with cash to spare.

Furthermore, Gilead Sciences pipeline is far more developed and ready to become a short-term catalyst that most GILD stock owners realize, explained here. When you start to look at all the moving parts, it is clear that Gilead stock is a terrific investment.

2017 remains a question for GILD stock

Despite being cheap with long-term catalysts, GILD investors must contend with sour sentiment. What Gilead needs most is a big acquisition, something for investors to get excited about. Receptos would have been the perfect acquisition, but Celgene already snatched it up. In looking throughout the biotech space, promising companies are too expensive, and others like Juno and Kite Pharma come with unknown safety questions that will be answered in ongoing trials.

The one company I’d like to see Gilead acquire is ACADIA Pharmaceuticals (NASDAQ:ACAD). Most would agree that where Gilead thrives is in marketing, and sales. Ironically, that’s where ACADIA Pharmaceuticals has trouble. With the right strategy, we believe that ACADIA’s drug Nuplazid could create several billion dollars in annual sales. However, ACADIA Pharmaceuticals needs help, and Gilead would be perfect to help.

With a $3 billion market capitalization, ACADIA Pharmaceuticals is the right fit for Gilead Sciences, an acquisition that GILD stock owners can get excited about. Still, the big question remains will Gilead make a move, for ACADIA or any other company? Regardless, Gilead stock is dirt cheap and should go much higher, but a big time acquisition would certainly accelerate the inevitable.

The rest of this content is exclusive to BNL Members only. (Unlock All Content & Much More)
  • Access all research reports, unlock hidden content, & follow stock coverage on more than 60 companies,
  • Know what stocks are being bought, sold, and held in the market beating BNL Portfolio, David's Dividend Portfolio, and Eddy's Options.
  • Get email notifications and mobile alerts the minute a trade is made. 
  • Join the fastest growing community of investors in the market, and engage with 100s of BNL Members in our Members Only section.

Learn More about BNL Membership and its no risk, no contract, guaranteed results policy!

Get our All Access Package for $85/month!

This entry was posted in 2017 Stock Outlook, Healthcare & Biotech, Members, Mergers & Acquisitions Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

One Trackback

  1. […] outstanding over the last three years. Furthermore, Gilead Sciences has $32 billion in cash. We are confident that GILD puts some of that cash to work in 2017 with […]

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!

%d bloggers like this: